首页> 外文期刊>The Tohoku Journal of Experimental Medicine >Overexpression of HOXA13 as a Potential Marker for Diagnosis and Poor Prognosis of Hepatocellular Carcinoma
【24h】

Overexpression of HOXA13 as a Potential Marker for Diagnosis and Poor Prognosis of Hepatocellular Carcinoma

机译:HOXA13的过表达作为肝细胞癌诊断和预后不良的潜在标志

获取原文
获取原文并翻译 | 示例
           

摘要

HOXA13 is a member of homeobox genes that encode transcription factors regulating embryonic development and cell fate. Abnormal HOXA13 expression was reported in hepatocellular carcinoma (HCC), but its correlation with tumor angiogenesis and prognosis still remain unclear. This study was aimed to uncover the expression, diagnostic and prognostic significance of HOXA13 in HCC. lmmunohistochemistry was performed to detect HOXA13 expression in HCC and corresponding paracarcinomatous tissues from 90 patients. Enzyme-linked immunosorbent assay was used to detect serum HOXA13 in 90 HCC patients and 20 healthy volunteers. Receiver operating characteristics was analyzed to calculate diagnostic accuracy of serum HOXA13, alpha-fetoprotein (AFP) and their combination. lmmunoreactivity of HOXA13 was detected in 72.2% of HCC, and 12.2% of adjacent non-cancerous samples. HOXA13 expression was significantly associated with tumor size, microvascular invasion, pathological grade, tumor capsula status, AFP level, tumor-node-metastasis stage and positively correlated with VEGF (p < 0.001) and microvessel density (p < 0.001). The combination of serum HOXA13 and AFP had a markedly higher area under the curve than HOXA13 alone. HOXA13 expression was associated with unfavorable overall survival (OS) (p < 0.001) and disease-free survival (DFS) (p < 0.001). Multivariate analysis indicated that patients with HOXA13-expressing tumors had a significantly shorter OS (p = 0.030) and DFS (p = 0.005) than those with HOXA13-negative tumors. Thus, HOXA13 expression possibly plays an important role in tumor angiogenesis, progression and prognosis of HCC. Moreover, we demonstrate that serum HOXA13 may serve as a biomarker for early HCC diagnosing and predicting outcome.
机译:HOXA13是同源盒基因的成员,其编码调节胚胎发育和细胞命运的转录因子。据报道HOXA13表达异常在肝细胞癌(HCC)中,但其与肿瘤血管生成和预后的相关性仍不清楚。这项研究旨在揭示HOXA13在肝癌中的表达,诊断和预后意义。免疫组化法检测90例肝癌及癌旁癌旁组织中HOXA13的表达。酶联免疫吸附法用于检测90例HCC患者和20例健康志愿者的血清HOXA13。分析接收者的工作特征以计算血清HOXA13,甲胎蛋白(AFP)及其组合的诊断准确性。在72.2%的HCC和12.2%的相邻非癌性样品中检测到HOXA13的免疫反应性。 HOXA13表达与肿瘤大小,微血管浸润,病理分级,肿瘤包膜状态,AFP水平,肿瘤淋巴结转移阶段显着相关,并与VEGF(p <0.001)和微血管密度(p <0.001)正相关。血清HOXA13和AFP的组合比单独的HOXA13具有明显更高的曲线下面积。 HOXA13的表达与总体生存率(OS)(p <0.001)和无病生存期(DFS)(p <0.001)相关。多变量分析表明,表达HOXA13肿瘤的患者的OS(p = 0.030)和DFS(p = 0.005)明显短于HOXA13阴性肿瘤的患者。因此,HOXA13表达可能在HCC的肿瘤血管生成,进展和预后中起重要作用。此外,我们证明血清HOXA13可以作为早期HCC诊断和预测结果的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号